The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

NCT07138755 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
Sintilimab
Adaptive Radiotherapy

Interventions

DRUG: Experimental

Sponsor

The Third Xiangya Hospital of Central South University